IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy

Stephen C. Dreskin, Matthew Germinaro, Dominik Reinhold, Xueni Chen, Brian P. Vickery, Michael Kulis, A. Wesley Burks, Surendra S. Negi, Werner Braun, Jeffery M. Chambliss, Spodra Eglite, Caitlin M.G. McNulty

Research output: Contribution to journalArticle

Abstract

Background: For patients with peanut allergy, there are currently no methods to predict who will develop sustained unresponsiveness (SU) after oral immunotherapy (OIT). Objective: Assess IgE binding to peanut (PN), Ara h 2, and specific linear epitopes of Ara h 2 as predictors of the important clinical parameters: eliciting dose threshold and attainment of SU following OIT. Methods: Samples and clinical data were collected from children undergoing OIT. PN- and Ara h 2-sIgE were quantified by ImmunoCAP®. IgE binding to linear peptides of Ara h 2 and Ara h 6 was measured with peptide microarrays. Results: Lower values of PN-sIgE correlated with eliciting dose (P =.001) and with a higher likelihood of achieving SU (P <.0001), but these relationships were lost at higher values for PN-sIgE (≥14 kIU for eliciting dose and ≥35 kIU/L for SU). In subjects with PN-sIgE ≥ 14 kIU/L, binding of IgE to epitopes 5 and 6 of Ara h 2 was associated with a lower eliciting dose at baseline challenge (P <.001; Pc <.02). In subjects with PN-sIgE ≥ 35 kIU/L, a combined model of IgE binding to epitopes 1, 5 and 6 with PN-sIgE was highly predictive of attainment of SU (AUC of 0.86; P =.0067). Conclusion: In young patients with peanut allergy, measurement of PN-sIgE and IgE binding to specific linear epitopes of Ara h 2 in baseline samples may allow stratification of patients regarding sensitivity to challenge and outcome of OIT.

Original languageEnglish (US)
JournalPediatric Allergy and Immunology
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Preschool Children
Immunotherapy
Immunoglobulin E
Epitopes
Peanut Hypersensitivity
Peptides
Arachis
Area Under Curve

Keywords

  • allergens
  • food allergy
  • IgE
  • immunotherapy
  • oral immunotherapy
  • peanut allergy
  • tolerance induction

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Immunology and Allergy
  • Immunology

Cite this

Dreskin, S. C., Germinaro, M., Reinhold, D., Chen, X., Vickery, B. P., Kulis, M., ... McNulty, C. M. G. (Accepted/In press). IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy. Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13117

IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy. / Dreskin, Stephen C.; Germinaro, Matthew; Reinhold, Dominik; Chen, Xueni; Vickery, Brian P.; Kulis, Michael; Burks, A. Wesley; Negi, Surendra S.; Braun, Werner; Chambliss, Jeffery M.; Eglite, Spodra; McNulty, Caitlin M.G.

In: Pediatric Allergy and Immunology, 01.01.2019.

Research output: Contribution to journalArticle

Dreskin, SC, Germinaro, M, Reinhold, D, Chen, X, Vickery, BP, Kulis, M, Burks, AW, Negi, SS, Braun, W, Chambliss, JM, Eglite, S & McNulty, CMG 2019, 'IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy', Pediatric Allergy and Immunology. https://doi.org/10.1111/pai.13117
Dreskin, Stephen C. ; Germinaro, Matthew ; Reinhold, Dominik ; Chen, Xueni ; Vickery, Brian P. ; Kulis, Michael ; Burks, A. Wesley ; Negi, Surendra S. ; Braun, Werner ; Chambliss, Jeffery M. ; Eglite, Spodra ; McNulty, Caitlin M.G. / IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy. In: Pediatric Allergy and Immunology. 2019.
@article{778aa86c554f481b88ad0c70200bbe64,
title = "IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy",
abstract = "Background: For patients with peanut allergy, there are currently no methods to predict who will develop sustained unresponsiveness (SU) after oral immunotherapy (OIT). Objective: Assess IgE binding to peanut (PN), Ara h 2, and specific linear epitopes of Ara h 2 as predictors of the important clinical parameters: eliciting dose threshold and attainment of SU following OIT. Methods: Samples and clinical data were collected from children undergoing OIT. PN- and Ara h 2-sIgE were quantified by ImmunoCAP{\circledR}. IgE binding to linear peptides of Ara h 2 and Ara h 6 was measured with peptide microarrays. Results: Lower values of PN-sIgE correlated with eliciting dose (P =.001) and with a higher likelihood of achieving SU (P <.0001), but these relationships were lost at higher values for PN-sIgE (≥14 kIU for eliciting dose and ≥35 kIU/L for SU). In subjects with PN-sIgE ≥ 14 kIU/L, binding of IgE to epitopes 5 and 6 of Ara h 2 was associated with a lower eliciting dose at baseline challenge (P <.001; Pc <.02). In subjects with PN-sIgE ≥ 35 kIU/L, a combined model of IgE binding to epitopes 1, 5 and 6 with PN-sIgE was highly predictive of attainment of SU (AUC of 0.86; P =.0067). Conclusion: In young patients with peanut allergy, measurement of PN-sIgE and IgE binding to specific linear epitopes of Ara h 2 in baseline samples may allow stratification of patients regarding sensitivity to challenge and outcome of OIT.",
keywords = "allergens, food allergy, IgE, immunotherapy, oral immunotherapy, peanut allergy, tolerance induction",
author = "Dreskin, {Stephen C.} and Matthew Germinaro and Dominik Reinhold and Xueni Chen and Vickery, {Brian P.} and Michael Kulis and Burks, {A. Wesley} and Negi, {Surendra S.} and Werner Braun and Chambliss, {Jeffery M.} and Spodra Eglite and McNulty, {Caitlin M.G.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/pai.13117",
language = "English (US)",
journal = "Pediatric Allergy and Immunology",
issn = "0905-6157",
publisher = "Blackwell Munksgaard",

}

TY - JOUR

T1 - IgE binding to linear epitopes of Ara h 2 in peanut allergic preschool children undergoing oral Immunotherapy

AU - Dreskin, Stephen C.

AU - Germinaro, Matthew

AU - Reinhold, Dominik

AU - Chen, Xueni

AU - Vickery, Brian P.

AU - Kulis, Michael

AU - Burks, A. Wesley

AU - Negi, Surendra S.

AU - Braun, Werner

AU - Chambliss, Jeffery M.

AU - Eglite, Spodra

AU - McNulty, Caitlin M.G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: For patients with peanut allergy, there are currently no methods to predict who will develop sustained unresponsiveness (SU) after oral immunotherapy (OIT). Objective: Assess IgE binding to peanut (PN), Ara h 2, and specific linear epitopes of Ara h 2 as predictors of the important clinical parameters: eliciting dose threshold and attainment of SU following OIT. Methods: Samples and clinical data were collected from children undergoing OIT. PN- and Ara h 2-sIgE were quantified by ImmunoCAP®. IgE binding to linear peptides of Ara h 2 and Ara h 6 was measured with peptide microarrays. Results: Lower values of PN-sIgE correlated with eliciting dose (P =.001) and with a higher likelihood of achieving SU (P <.0001), but these relationships were lost at higher values for PN-sIgE (≥14 kIU for eliciting dose and ≥35 kIU/L for SU). In subjects with PN-sIgE ≥ 14 kIU/L, binding of IgE to epitopes 5 and 6 of Ara h 2 was associated with a lower eliciting dose at baseline challenge (P <.001; Pc <.02). In subjects with PN-sIgE ≥ 35 kIU/L, a combined model of IgE binding to epitopes 1, 5 and 6 with PN-sIgE was highly predictive of attainment of SU (AUC of 0.86; P =.0067). Conclusion: In young patients with peanut allergy, measurement of PN-sIgE and IgE binding to specific linear epitopes of Ara h 2 in baseline samples may allow stratification of patients regarding sensitivity to challenge and outcome of OIT.

AB - Background: For patients with peanut allergy, there are currently no methods to predict who will develop sustained unresponsiveness (SU) after oral immunotherapy (OIT). Objective: Assess IgE binding to peanut (PN), Ara h 2, and specific linear epitopes of Ara h 2 as predictors of the important clinical parameters: eliciting dose threshold and attainment of SU following OIT. Methods: Samples and clinical data were collected from children undergoing OIT. PN- and Ara h 2-sIgE were quantified by ImmunoCAP®. IgE binding to linear peptides of Ara h 2 and Ara h 6 was measured with peptide microarrays. Results: Lower values of PN-sIgE correlated with eliciting dose (P =.001) and with a higher likelihood of achieving SU (P <.0001), but these relationships were lost at higher values for PN-sIgE (≥14 kIU for eliciting dose and ≥35 kIU/L for SU). In subjects with PN-sIgE ≥ 14 kIU/L, binding of IgE to epitopes 5 and 6 of Ara h 2 was associated with a lower eliciting dose at baseline challenge (P <.001; Pc <.02). In subjects with PN-sIgE ≥ 35 kIU/L, a combined model of IgE binding to epitopes 1, 5 and 6 with PN-sIgE was highly predictive of attainment of SU (AUC of 0.86; P =.0067). Conclusion: In young patients with peanut allergy, measurement of PN-sIgE and IgE binding to specific linear epitopes of Ara h 2 in baseline samples may allow stratification of patients regarding sensitivity to challenge and outcome of OIT.

KW - allergens

KW - food allergy

KW - IgE

KW - immunotherapy

KW - oral immunotherapy

KW - peanut allergy

KW - tolerance induction

UR - http://www.scopus.com/inward/record.url?scp=85074370191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074370191&partnerID=8YFLogxK

U2 - 10.1111/pai.13117

DO - 10.1111/pai.13117

M3 - Article

C2 - 31437325

AN - SCOPUS:85074370191

JO - Pediatric Allergy and Immunology

JF - Pediatric Allergy and Immunology

SN - 0905-6157

ER -